2025 Targeted Therapies of Lung Cancer (TTLC) - Posters-PP01.25 Real-world demographics, clinical characteristics, and overall survival (OS) among Canadian patients (pts) with advanced EGFR-mutated non-small cell lung cancer (NSCLC) treated with first-line osimertinib (CARMA-BROStudy; NCT04151342)

PP01.25 Real-world demographics, clinical characteristics, and overall survival (OS) among Canadian patients (pts) with advanced EGFR-mutated non-small cell lung cancer (NSCLC) treated with first-line osimertinib (CARMA-BROStudy; NCT04151342)

Back to course

Pdf Summary

The CARMA-BRO Study investigates the real-world demographics, clinical characteristics, and overall survival (OS) of Canadian patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC) treated with first-line osimertinib. Osimertinib, an EGFR-tyrosine kinase inhibitor, is the preferred first-line treatment for patients with this mutation. While clinical trials like FLAURA have demonstrated its efficacy, this study evaluates its real-world effectiveness across four Canadian centers (Ontario, Quebec, and Nova Scotia).<br /><br />The study included 151 patients diagnosed between December 2014 and December 2021. Analysis excluded those without completed molecular testing identifying a common EGFR mutation (exon 19 del or exon 21 L858R). Key findings include a median OS of 34.7 months (95% CI: 28.8-NR) across the cohort. Age was significantly associated with OS, with older age linked to poorer outcomes (adjusted hazard ratio of 1.03, p=0.029). However, other potential factors such as baseline comorbidities and number of extra-thoracic metastatic sites did not reach statistical significance in association with OS.<br /><br />Of the cohort, 66 patients (44%) remained on osimertinib, while the remainder discontinued, primarily due to disease progression or death. Temporary dose modifications due to adverse events were reported in 6% of cases. The study’s results indicated that Canadian real-world OS aligns with the FLAURA trials, supporting osimertinib’s use in a broader, heterogeneous population.<br /><br />The study suggests that future analyses could extend to other Canadian centers to enhance generalizability and explore additional factors influencing OS. This real-world data informs clinicians about osimertinib’s efficacy in routine clinical practice, confirming its benefits while highlighting areas for further research. The study is funded by AstraZeneca Canada Inc.

Asset Subtitle

Luna Jia Zhan

Keywords

CARMA-BRO Study

EGFR-mutated NSCLC

osimertinib

real-world effectiveness

Canadian centers

overall survival

FLAURA trials

AstraZeneca Canada

clinical characteristics

advanced lung cancer